



# LIVED AND LIVING EXPERIENCE

**CHAIR: JANE MORETON, VAADA**

1. Tackling Stigma  
through Co-design

1. Integrating complex  
client needs into the  
treatment of  
benzodiazepine  
dependence: evolving  
service design

1. Elevating consumer  
voices - consumer  
participation in  
practice

---

## Platinum Sponsors





# Tackling Stigma through Co-design

## Tina Lam, MARC

Kirsty Morgan, Peninsula Health  
Jessica Reece, Peninsula Health

Platinum Sponsors





Peninsula  
Health



Amelia Berg, Lived  
Experience Researcher



Dr Tina Lam,  
Senior Research Fellow

Kirsty Morgan, AOD Educator  
Jessica Reece, AOD Lived Experience  
Educator

# Tackling Stigma through Co-Design

# Acknowledgment of Country





# Recognition of Lived Experience

We acknowledge people with lived experience of substance dependence and the experiences of those who support them.

We recognise the vital contribution of lived experience at all levels & that the voices of people with lived experience inform our work.



# What is our working definition of Co-design?


A process where people in lived experience, clinical, education or academic roles, **partner as equals** to improve health services by listening, learning and making decisions together



# Linking Co-designed Research & AOD Education

AOD Patient Journey  
Study  
(Academics & LE  
Researcher)

- What are the barriers/enablers to treatment access through hospital & community services?



AOD Education  
program for Hospital-  
based clinicians  
(AOD Educator & LE  
Educator)

- Aims to improve capability of nurses & junior medical staff to provide care for inpatients with co-occurring AOD needs

# What is Lived Experience?

## What is a Lived Experience Peer Researcher?

- People with lived or living experience have either a history, or current experience, of a particular issue, or have been impacted by another person's experiences.
- Lived Experience Peer Researchers have a declared experience of the issue the research is focused on and are recognized as a peer by the community.
- Co-design and co-production- involve us at all stages of the research process- this is meaningful involvement and will make your research more relevant and responsive to the needs of the community.
- When choosing things you would like to research, consult with the affected community FIRST to see what the community's needs and priorities are



# Why work with a lived experience peer researcher?



- Ensuring adequate training and support in place for peer researchers
- Dual-interviewing has the potential to create power imbalances



- We have close connections with community
- Participants can feel more comfortable when a peer is involved
- Peers act as a “bridge” between academic researchers and the community to mitigate power imbalances
- Unique insights come from lived experience
- Shared learning and support
- Data will be richer

# “Mapping the Alcohol and Other Drug Patient Journey” Study

Research Aims: To improve care in the Frankston and Mornington Peninsula region by understanding alcohol and other drug treatment journeys through:

- mapping people’s experiences;
- identifying barriers and facilitators from a patient/consumer perspective;
- identifying barriers and facilitators from a service organisation perspective; and
- identifying how treatment journeys can be improved.

# Findings – High Level Themes

## From Lived Experience:

- difficulty in locating services;
- poor or no responses from services;
- **stigma from staff;**
- alcohol and other drug use (current/historical) exclusionary to service access;
- unstable housing for women; and
- inexperienced alcohol and other drug specialist staff.

## From Service Providers:

- structured service delivery processes and procedures (including frequency of intakes and assessments without bridging support);
- **stigma from staff;**
- long times on wait lists; and
- lack of collaborative cross-sector relationships.

# Findings: What people told us

*"I get so hurt, like people and their bloody judgment"*  
(C52F).

*We "... meet them, greet them, treat them, and street them"*  
(HS119M)

*"I know we're all drug addicts and that, but don't speak to us like we're drug addicts. It's fucking rude. We get it, we get what we are, but we're trying to get help, that's why we're here, so treat us like humans, don't treat us like we are drug addicts ... people aren't going to respond well to being treated like shit"*  
(C35M)

*"I couldn't tell you that there were definite remarks that I heard, but I felt like it was just 'alright get him better, flush out his system, and kick him out' that was my feeling ... that was definitely my feeling on every occasion I'd have to say"* (C37M)

*"And it is embarrassing and it makes you not want to reach out to get help"*  
(C39M).

*"You're doing this to yourself. You're not sick. This person with the heart attack that is our sick patient, this person is just wasting our time"*  
(HS104M)

# Why involve an illustrator in research?

## Traditional outputs

- Too much text, complex statistics
- Narrow audience

## Illustrated summaries

- Intuitively understood
- common understanding between stakeholders

Poisson regression to generate incident rate ratios (IRRs) to estimate the supply-adjusted rate of ED presentation of each opioid (the outcome variable) and how the rate changed over time (the predictor). The primary analysis considered each of the opioid categories as mutually exclusive—that is, a presentation was included in the rate calculation where the specific opioid was the only opioid involved in the presentation (Table 1). A sensitivity analysis explored the effect of selecting single-opioid poisonings versus multiple opioid poisonings. To this effect, rates were calculated using presentations where the specific opioid was the only opioid involved or was one of multiple opioids involved in the presentation (Supporting information, Table S3). Supply-adjusted rates were not calculated for the 'multiple opioids' category due to the heterogeneity of the OME denominator for each presentation. Rates were aggregated over 6-month periods for analyses to enable minimum cell sizes of five, and were presented by year for ease of interpretation.

### Aim 2: characteristics of presentations

We used multinomial logistic regression to analyze opioid-poisoning characteristics to explore how opioid type varies by presentation characteristic. Opioid type was the outcome variable in all regressions, with morphine serving as the reference category (the standard reference opioid for calculating opioid doses [24]). Separate regressions were run, with each of the eight characteristics serving as the primary independent variable. Year was included in all models as a secondary independent variable to assess whether the opioid type variation by

presentation characteristic varied over time. The regressions also controlled for age and sex (see Supporting information, Figs S3–S10). Categories were aggregated where necessary to ensure that all analyses reported cell sizes of at least five. All quantitative analyses were conducted in SAS or Stata, with P-values less than 0.05 considered significant with no correction for multiple testing [25].

### Missing data

There were minimal missing data (< 5%), with fewer than five presentations missing data for sex, 75 with a missing birth country and 59 with unknown geographical region (which was grouped with overseas and interstate presentations for the purpose of analysis). Presentations with unknown geographical region were a subset of the 118 presentations with missing data for SEIFA, which is calculated based on postcode. With the exception of country of geographical region, all missing data were handled via list-wise deletion in the multinomial regression.

We could not locate codeine content information on 'Chemists Own Cough Suppression Linctus 200 ml' from the previous or current brand owners (Aspen and Arrow). Available data states 6858 units were sold January–August 2009 to August 2010 (of more than 63 million total codeine units supplied in the study period, or approximately 0.1% of all codeine sales). These units did not contribute to the total volume of codeine used to calculate supply-adjusted rates.


Opioid categories		RR	CI	RR	CI	RR	CI	RR	CI	RR	CI	RR	CI			
4–5		1.02	0.41	1.69	0.73	0.35	1.52	0.38	0.07	1.97	0.89	0.51	1.54	0.70	0.38	1.21
6–7		0.77	0.49	1.23	0.81	0.43	1.54	0.66	0.27	2.71	0.90	0.55	1.49	0.79	0.46	1.27
8		1.35	0.79	2.31	1.06	0.52	2.16	1.27	0.39	4.12	0.92	0.51	1.66	1.03	0.53	1.95
9–10 (not subtyped)		0.76	0.47	1.24	0.65	0.31	0.94	1.07	0.39	4.06	0.72	0.42	1.22	0.71	0.39	1.27
Year		1.19	1.13	1.26	1.55	1.42	1.69	2.19	1.76	2.75	1.58	1.11	1.28	1.19	1.11	1.27
Intent		RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR
Intentional self-harm		0.57	0.45	0.78	0.49	0.32	0.77	0.43	0.21	0.91	0.55	0.29	0.76	0.40	0.27	0.59
Other		1.19	1.13	1.26	1.55	1.42	1.69	2.19	1.76	2.75	1.58	1.11	1.28	1.19	1.11	1.27
Admission outcome <sup>a</sup>		RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR
Admission		1.53	1.13	2.08	1.54	1.12	2.70	1.22	0.58	2.54	1.07	0.77	1.50	1.11	0.77	1.61
Presentation only		1.21	1.14	1.28	1.57	1.44	1.71	2.24	1.80	2.78	1.58	1.11	1.26	1.19	1.11	1.27
Triage category		RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR	RR
Requires immediate treatment		1.52	1.11	2.10	1.51	0.94	2.42	1.34	0.97	3.48	1.45	1.16	2.36	0.94	0.63	1.40
Does not require immediate treatment		1.30	1.14	1.27	1.55	1.42	1.70	2.24	1.80	2.78	1.58	1.11	1.26	1.19	1.11	1.27
Year		1.19	1.13	1.26	1.55	1.42	1.69	2.19	1.76	2.75	1.58	1.11	1.28	1.19	1.11	1.27

Abbreviations: RR = relative risk ratio; CI = confidence interval; OI = overseas.

Proportion of opioid which contained morphine from the classification for the regression: age (0.4%), sex (0.5%), admission (0.2%), country of birth (0.4%), intent (0.7%), region (7.7%), SEIFA quartile (0.2%) and triage (0.8%). All models controlled for age and sex.

<sup>a</sup>SEIFA is a proxy for socioeconomic status; categories were split to reflect approximately evenly sized populations for the analysis.

<sup>b</sup>Presentation only includes discharge to home with no treatment, admitted, admission outside of the same hospital or another hospital campus.








# Process for developing posters

## 1. Iterative process refining the content & poster structure

Content from n=40 participants (AOD CAG, clinicians). Then, weekly collaborations between the illustrator & the academic & LE research team.



## 2. Workshops

Same interviewees who contributed the original content

### YOUR LANGUAGE MATTERS: A CLINICIAN'S GUIDE

ONE BAD ENCOUNTER CAN PUT SOMEONE OFF SEEKING HELP FOR YEARS



## 3. Final version

Incorporating workshop feedback & checking referral pathways

### YOUR LANGUAGE MATTERS: A CLINICIAN'S GUIDE

ONE BAD ENCOUNTER CAN PUT SOMEONE OFF SEEKING HELP FOR YEARS



# ALCOHOL & OTHER DRUGS: YOUR LANGUAGE MATTERS!

THINK ABOUT the WORDS YOU USE with PATIENTS, FAMILIES, and CARERS WHEN TALKING ABOUT ALCOHOL & DRUGS.

IT CAN SIGNIFICANTLY IMPACT their CARE and ASKING for HELP!



**INSTEAD  
of SAYING...**



JUNKIE  
DRUG USER/  
ABUSER  
DRUG ADDICT  
ALCOHOLIC

SUBSTANCE  
ABUSE  
MISUSE  
NON-COMPLIANT  
USE



CLEAN/SOBER  
EX-ADDICT  
FORMER ADDICT  
USED to be  
a JUNKIE



**SAY THIS...**



PERSON WHO  
USES ALCOHOL or  
OTHER DRUGS  
EXPERIENCING  
SUBSTANCE  
DEPENDENCE  
PERSON with AOD  
CONCERNS

HIGH-RISK  
SUBSTANCE USE  
NON-  
PRESCRIBED  
USE



CURRENTLY  
ABSTINENT  
NO LONGER  
SUBSTANCE  
DEPENDENT  
PERSON WITH LIVED  
EXPERIENCE OF DRUG  
USE /DEPENDENCE

## Posters developed through AOD Patient Journey Study and with AOD Consumer Advisory Group

### YOUR LANGUAGE MATTERS: A CLINICIAN'S GUIDE

ONE BAD ENCOUNTER CAN PUT SOMEONE OFF SEEKING HELP for YEARS



WHEN I HEAR...



IT'S JUST ANOTHER  
DRUG USER  
YOU'RE NOT  
REALLY SICK,  
I'VE GOT REAL  
PATIENTS  
THEY NEVER  
SEEM to LEARN.  
WHAT'S the POINT?  
YOU'RE DOING  
THIS to YOURSELF  
YOU'RE TOO HARD  
to DEAL WITH

I FEEL...



YOU CAN'T UNDERSTAND  
MY PROBLEMS WITHOUT  
KNOWING MY STORY  
THIS MAKES ME  
FEEL WORTHLESS  
YOU DON'T  
BELIEVE ME  
YOU DON'T WANT  
TO HELP ME  
THIS IS  
HUMILIATING

I'D LIKE to HEAR...



I WANT to  
HELP YOU  
TELL ME ABOUT  
WHAT'S BEEN  
HAPPENING  
FOR YOU  
WE'RE NOT HERE  
to JUDGE YOU  
LET'S MAKE a  
PLAN TOGETHER

# Tackling language & stigma with a co-designed social marketing & education

## Multiple & Combined interventions:

- Posters
- Virtual background for online meetings
- E-newsletter
- Staff & team meeting
- Online self-complete course
- In-services on the ward
- Revising clinical tools & templates
- Local leads to be in-situ






# Your language matters




**Fiona Reed**

Executive Director Nursing & Midwifery, Peninsula Health



**Bel Berry**

Director of Complex Services



**Emma**

Lived Experience

# Campaign Reach

- ✓ 533 viewed newsletter article
- ✓ 374 staff participated in training sessions
- ✓ 154 views of video
- ✓ Posters on display across 6 wards, ED and some other community sites (distribution ongoing)



## Feedback


*“It really built my empathy and hearing from a lived experience worker about what happened after her hospitalisation and how screening & help could have made a difference made a really powerful impact” (Nurse, ED)*

*“Congrats on delivering a great course, should I work clinically again or work with consumers who have a drug dependence I will be more aware of my language” (Improvement & Innovation Project Officer)*




# Reflections from Lived Experience Educator

- Importance of co-design with people with lived experience – more than just a voice
- Impact of sharing story
- Empowering
- Co-facilitated deliver of interventions to change healthcare providers perceptions



## Lessons Learnt

- Value of LE Researchers & LE Educators
- Co-design materials during study (action research) to produce outputs (posters) better enables translation of findings into practice
- Development & delivery of education with lived experience makes it more impactful
- Relationships, relationships, relationships!



# Thank you!

**Kirsty Morgan**

AOD Educator  
Mental Health Learning Hub  
Mobile 0423 162 850  
[KMorgan@phcn.vic.gov.au](mailto:KMorgan@phcn.vic.gov.au)

**Jessica Reece**

AOD Care and Recovery Clinician & Lived Experience Educator  
Frankston and Mornington Drug and Alcohol Services  
Mobile 0417 188 243  
[jreece@phcn.vic.gov.au](mailto:jreece@phcn.vic.gov.au)

**Amelia Berg**

APSU and Fuse Initiatives Project Worker  
Association of Participating Service Users  
Self Help Addiction Resource Centre Inc.  
[Aberg@sharc.org.au](mailto:Aberg@sharc.org.au)

**Tina Lam**

Senior Research Fellow  
Monash Addiction Research Centre  
[Tina.Lam@monash.edu](mailto:Tina.Lam@monash.edu)

We'd also acknowledge and thank Prof. Suzanne Nielsen, Dr Leanne Francia, Dr Michael Savic and Prof. Dan Lubman, investigators on the AOD Patient Journey Study, and Peninsula Health's Consumer Advisory Group.